VA CSP #553:高危前列腺癌根治术后多西他赛联合泼尼松辅助化疗的III期随机研究
VA CSP #553研究旨在评估高危前列腺癌根治术后在标准治疗基础上加用辅助化疗的疗效。研究将术后患者随机分为观察组(标准治疗)或多西他赛联合泼尼松组(每3周一次,共6周期)。计划入组636例,实际随机298例。主要终点无进展生存期(PFS)在两组间无统计学差异(中位PFS:化疗组55.5个月 vs 标准治疗组42.2个月;校正HR 0.80,95%CI 0.58-1.11;p=0.18)。预设亚组分析显示肿瘤分期≥T3b(HR 0.54,95%CI 0.32-0.92;p=0.022)和Gleason评分≤7(HR 0.65,95%CI 0.43-0.99;p=0.046)的患者可能从化疗中获益。
要点
- 在高危前列腺癌根治术后患者中,多西他赛联合泼尼松辅助化疗未显著改善整体人群的PFS。
- 亚组分析提示肿瘤分期≥pT3b或Gleason评分≤7的患者可能从辅助化疗中获益。
- 化疗相关≥3级不良事件常见中性粒细胞减少(43%)和高血糖(20%),发热性中性粒细胞减少发生率为2%。
核心结论
- 在高危前列腺癌根治术后患者中,多西他赛联合泼尼松辅助化疗未显著改善意向治疗人群的无进展生存期。
- 由于入组受限导致研究把握度不足,亚组分析提示Gleason评分≤7和分期≥pT3b的患者可能获益。
研究设计与样本
- 研究为III期随机对照试验(VA Cooperative Studies Program #553),纳入根治术后高危前列腺癌患者。
- 患者随机接受标准治疗(观察)或多西他赛联合泼尼松化疗(每3周一次,共6周期)。
- 随机化按前列腺特异性抗原、Gleason评分、肿瘤分期和手术切缘状态分层。
- 计划入组636例,实际随机298例;中位随访59.1个月(范围0.2-103.7个月)。
主要发现
- 主要终点PFS在两组间无统计学差异(中位PFS:化疗组55.5个月 vs 标准治疗组42.2个月;校正HR 0.80,95%CI 0.58-1.11;p=0.18)。
- 预设亚组分析显示肿瘤分期≥T3b的患者PFS获益(HR 0.54,95%CI 0.32-0.92;p=0.022)。
- Gleason评分≤7的患者也显示PFS获益(HR 0.65,95%CI 0.43-0.99;p=0.046)。
- 次要终点分析因事件率低而受限。
- 常见≥3级不良事件包括中性粒细胞减少(43%)、高血糖(20%)和乏力(5%),发热性中性粒细胞减少发生率为2%。
临床怎么用
- 对于高危前列腺癌根治术后患者,不推荐常规添加多西他赛联合泼尼松辅助化疗。
- 对于肿瘤分期≥pT3b或Gleason评分≤7的高危患者,可考虑个体化讨论辅助化疗的潜在获益。
- 辅助化疗需权衡毒性,特别是中性粒细胞减少和高血糖等不良事件。
局限性
- 实际入组298例,低于计划的636例,导致研究把握度不足。
- 次要终点分析因事件率低而受限。
- 亚组分析结果需谨慎解读,可能存在多重比较和偶然性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Veterans Affairs Cooperative Studies Program study #553 was designed to evaluate the efficacy of adjuvant chemotherapy added to the standard of care (SOC) for patients who are at high risk for relapse after prostatectomy. OBJECTIVE: To test whether addition of chemotherapy to surgery for high-risk prostate cancer improves progression-free survival (PFS). DESIGN, SETTING, AND PARTICIPANTS: Eligible patients after prostatectomy were randomized to the SOC group with observation or to the chemotherapy group with docetaxel and prednisone administered every 3 wk for six cycles. Randomization was stratified for prostate-specific antigen, Gleason, tumor stage, and surgical margin status. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was PFS. Secondary endpoints included overall, prostate cancer-specific, and metastasis-free survival, and time to androgen deprivation therapy. RESULTS AND LIMITATIONS: A total of 298 of the planned 636 patients were randomized. The median follow-up was 59.1 mo (0.2-103.7 mo). For the primary endpoint, the two groups did not statistically differ in PFS (median 55.5 mo in the chemotherapy group and 42.2 mo in the SOC group; test adjusted for site via gamma frailty p=0.21; adjusted hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.58-1.11; p=0.18). Prespecified subgroup analyses showed benefit in PFS for patients with tumor stage ≥T3b (HR 0.54, 95% CI 0.32-0.92; p=0.022) and patients with Gleason score ≤7 (HR 0.65, 95% CI 0.43-0.99; p=0.046). Secondary endpoint analyses are hampered by low event rates. The most common adverse events (≥grade 3 related or possibly related to chemotherapy) included neutropenia (43%), hyperglycemia (20%), and fatigue (5%), with febrile neutropenia in 2%. CONCLUSIONS: Adjuvant chemotherapy in high-risk prostate cancer using docetaxel and prednisone did not lead to statistically significant improvement in PFS for the intention-to-treat population as a whole. The analysis was challenged by lower power due to accrual limitation. Subgroup analyses suggest potential benefit for patients with Gleason grade ≤7 and stage≥pT3b (ClinicalTrials.gov number NCT00132301). PATIENT SUMMARY: In this randomized trial, we tested whether addition of chemotherapy to surgery for high-risk prostate cancer decreased the risk of prostate-specific antigen rise after surgery. We found no benefit from docetaxel given after radical prostatectomy, although some subgroups of patients may benefit.
引用
- Lin DW, Shih MC, Aronson W, et al. Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. Eur Urol. 2020. PMID: 31924316. doi:10.1016/j.eururo.2019.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。